MNG1230
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.322
- PANCREAS_BETA_CELLS+0.294
- KRAS_SIGNALING_DN+0.267
- ESTROGEN_RESPONSE_LATE+0.179
- MYOGENESIS+0.177
- XENOBIOTIC_METABOLISM+0.138
- ESTROGEN_RESPONSE_EARLY+0.055
- COAGULATION+0.047
- BILE_ACID_METABOLISM+0.021
- HEDGEHOG_SIGNALING+0.017
Top 10 suppressed
- MYC_TARGETS_V1-0.570
- PROTEIN_SECRETION-0.556
- UNFOLDED_PROTEIN_RESPONSE-0.479
- G2M_CHECKPOINT-0.460
- E2F_TARGETS-0.442
- MITOTIC_SPINDLE-0.423
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- UV_RESPONSE_DN-0.396
- MTORC1_SIGNALING-0.391
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD014_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.940 |
| 2 | SJEPD031_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.921 |
| 3 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.912 |
| 4 | MDT-AP-0123 | Med | Medulloblastoma | 0.909 |
| 5 | MNG339 | — | — | 0.906 |
| 6 | SRR1320342 | GTEX | — | 0.905 |
| 7 | BS_7B89YR6K | EPN | Posterior Fossa EPN | 0.903 |
| 8 | BS_TCGEZJ5F | Supratentorial Ependymoma | — | 0.901 |
| 9 | SRR1472663 | GTEX | — | 0.900 |
| 10 | MNG1256 | — | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.322 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.294 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.267 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.179 | Idelalisib | — uncovered |
| MYOGENESIS | 0.177 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.138 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.055 | Inavolisib | — uncovered |
| COAGULATION | 0.047 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.021 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.017 | Inavolisib | — uncovered |
| COMPLEMENT | 0.013 | Inavolisib | — uncovered |
| PEROXISOME | 0.003 | Idelalisib | — uncovered |